GLSI Greenwich LifeSciences, Inc. Insider Trading

CEO/CFO Patel buys 3,600 shares (3.6K) at $13.06 avg amid -39.7% 30-day drop; company unprofitable ($-5.7M net income).

Snehal Patel, CEO and CFO, executed 2 separate purchases totaling 3,600 shares for $47,018.00 on consecutive days (2,500 shares at $13.14 on July 23 and 1,100 shares at $12.88 on July 24), at a blended average price of $13.06. The transaction occurs as the stock trades at $12.98, down -39.7% over 30 days and -61.9% from its 52-week high of $34.10, suggesting a significant recent decline. Patel's same-ticker purchase history at GLSI shows mixed timing: 2 of 5 prior buys were well-timed at the 90-day mark, with notably strong outcomes on the December 2025 purchases (+111.6% and -1.1% at 90 days respectively), but the most recent January 2026 purchases underperformed (-13.7% and -6.4% at 90 days). Against this backdrop, the company reported a full-year net loss of $-5,657,137.00, meaning Patel is accumulating shares in an unprofitable entity during a period of acute price weakness.

CEO/CFO Patel buys 1,800 shares at $29.83 on 2026-01-13; stock -7.2% from 52-week high. GLSI unprofitable ($-4.2M net income).

Patel Snehal, serving as both CEO and CFO, purchased 1,800 shares at $29.83 on 2026-01-13, just 70 cents below the 52-week high of $29.29. The stock currently trades at $27.19, -7.2% from that peak. While the open-market buy occurred during strong recent momentum (30-day change: +161.4%), the company's fundamentals remain challenged: the most recent fiscal year produced net income of $-4,151,845.00. Patel's cross-ticker track record shows a 30.77% win rate at the 90-day horizon with an average 90-day return of -9.2%, and his five prior GLSI-specific purchases remain too recent for measurable outcomes, limiting backward-facing signals about his timing ability at this ticker.

CEO/CFO Patel buys 2,900 shares at $27.54 on 2026-01-12 despite negative $-4.2M net income; stock +184.1% in 30 days from depressed levels.

Patel Snehal, CEO and CFO, purchased 2,900 shares at $27.54 on 2026-01-12 for a total value of $79,866.00, increasing his holdings to 5,602,302 shares. The purchase occurs in the context of substantial recent price appreciation: the stock stands at $29.29 currently, representing a 30-day gain of +184.1% and 90-day gain of +201.3%. However, the company reported a negative net income of $-4.2M over its most recent full fiscal year, indicating the business remains unprofitable. The insider's cross-ticker track record shows mixed timing results—20 prior buys averaged a 30-day return of +9.4% but a 90-day return of -9.2% with a 30% win rate—suggesting his historical open-market purchases have not consistently captured sustained gains. At this specific ticker (GLSI), his most recent measurable prior buy from 2025-11-25 showed a 30-day return of +105.6%, but the filing notes that 0 of his prior buys at GLSI were well-timed at the 90-day mark. The timing and magnitude of this buy during an extreme rally in an unprofitable company warrant investor attention to the fundamentals and sustainability of the recent price movement.

CEO/CFO Patel buys 4,300 shares of GLSI at $21.36 on 2025-12-31; holds 5.60M post-transaction.

Snehal Patel, serving as both CEO and CFO, purchased 4,300 shares at $21.36 on 2025-12-31, bringing his total holdings to 5,599,402 shares. This marks the third consecutive day of open-market purchases by the same insider (buys also occurred 2025-12-30 and 2025-12-18), occurring during a period of substantial near-term gains—the stock is up 137.2% over the prior 30 days and up 88.9% over 90 days, putting current price $21.21 at 14.4% below the 52-week high of $24.78. However, context is critical: the company reported a full-year net loss of $4,151,845, and his same-ticker buy history shows a mixed track record—of five prior buys at GLSI, only one with measurable 90-day outcome (the 2025-10-31 purchase) registered a loss. The pattern of consecutive day purchases near recent highs, combined with substantial unrealized losses on an unprofitable company, presents a potential liquidity or portfolio-realignment signal rather than one of fundamental conviction in recovery.

GLSI CEO Patel bought 2,900 shares at $21.73 on 2025-12-30 (current: $19.47, -21.4% from 52-week high).

Patel Snehal, CEO and CFO of Greenwich LifeSciences, purchased 2,900 shares at $21.73 for $63,017.00, bringing his holdings to 5,595,102 shares. The purchase occurs within the stock's elevated 30-day window (+131.5%) but occurs at a price -21.4% below the 52-week high of $24.78. His same-ticker history shows 5 prior buys at GLSI with mixed near-term results: the most recent measurable trade (2025-11-25 buy) returned +105.6% at 30 days, but earlier trades showed smaller gains or losses. His cross-ticker track record of 20 prior buys averaged +7.8% return at 30 days but only -8.9% at 90 days, with a 33.33% win rate at the 90-day horizon, suggesting a pattern of early strength followed by weakness. The company remains unprofitable with full-year net income of $-4,151,845.00 and a market cap of $269,747,874.33, which establishes an unprofitable fundamental backdrop for this insider transaction.

CEO Patel Snehal buys 4,100 GLSI shares at $12.62; 5th purchase in 6 weeks as stock rallies +60.0% (30d).

Patel Snehal, CEO and CFO, purchased 4,100 shares at $12.62 on 2025-12-18, bringing post-transaction holdings to 5,592,202 shares. This marks the fifth open-market buy at GLSI in a compressed 6-week window (purchases on 2025-04-17, 2025-04-25, 2025-10-31, 2025-11-07, and 2025-11-25, followed by this December 18 trade). The stock has appreciated +60.0% over the prior 30 days and +13.5% over 90 days, currently trading at $13.01 against a 52-week high of $13.81. At the same-ticker level, 2 of 2 measurable prior buys generated positive 90-day returns (+16.3% and +24.6%), suggesting a pattern of well-timed accumulation at this ticker. However, the company reported a negative net income of $-4,151,845.00 for its most recent full fiscal year, indicating ongoing unprofitability despite recent stock momentum. The rapid sequence of purchases during a sustained price rally, combined with persistent operating losses, creates a tension between insider conviction and fundamental cash-flow constraints.

CEO/CFO Patel buys 4,600 GLSI shares at $8.37; stock -41.6% from 52-week high; repeat buyer at this ticker with 3 of 3 prior buys well-timed at 90-day horizon.

Patel Snehal, CEO and CFO, purchased 4,600 shares of Greenwich LifeSciences at $8.37 on 2025-11-25, increasing holdings to 5,588,102 shares. This is his second buy in less than three weeks (prior buy on 2025-11-07), continuing a pattern of repeated acquisitions at this ticker. Notably, his prior trades at GLSI show a strong pattern: all 3 measurable buys (2025-04-07, 2025-04-17, 2025-04-25) delivered positive 90-day returns ranging from +10.2% to +24.6%, with the 30-day returns also positive in two of three instances. However, context matters: the stock is currently -41.6% from its 52-week high of $14.95, down -24.0% over 90 days and -4.6% over 30 days. The company is unprofitable, with net income of $-4,151,845.00 over its most recent full fiscal year. The repeated buying at declining prices, combined with the company's negative earnings, suggests either conviction that the current valuation presents opportunity or continued accumulation amid headwinds.

CEO Patel repurchases 10,600 GLSI shares at $8.43 amid -44.4% YTD retreat; stock down 31.1% in 90 days, company unprofitable ($-4.0M net income).

Patel Snehal (CEO and CFO) purchased 10,600 shares at $8.43 on 2025-11-07, bringing his post-transaction holdings to 5,583,502 shares. The transaction occurs while GLSI trades -44.4% from its 52-week high and has declined 31.1% over the past 90 days, significantly underperforming the broader market. Notably, his 4 prior open-market purchases at GLSI showed positive 90-day returns (+16.3%, +24.6%, +10.2%, +14.9%), establishing a pattern of well-timed accumulation at this ticker. However, this latest purchase comes against a backdrop of net income of $-4,025,278.00 for the most recent full fiscal year and a current price of $8.32 (down 19.2% over 30 days from the transaction), which may warrant scrutiny into the macro drivers of the decline and whether fundamentals justify the executive's continued accumulation.

GLSI CEO/CFO Patel buys 2,300 shares at $9.26; stock down 45.9% from 52-week high, company posting $-4.0M net loss.

Patel Snehal, serving as both CEO and CFO of Greenwich LifeSciences, purchased 2,300 shares at $9.26 on 2025-10-31, increasing holdings to 5,572,902 shares. The purchase occurs in a stressed context: GLSI's stock has declined 45.9% from its 52-week high of $14.95, trades 25.8% below its 30-day average, and the company reported a net loss of $-4,025,278.00 for its most recent full fiscal year. At this ticker, Patel's prior transaction history shows mixed timing: 4 of his 5 preceding GLSI purchases posted positive 90-day returns (April trades and January trade outcomes), though his cross-ticker track record averages -8.3% over 90 days with only a 30% win rate. The current price of $8.09 sits below his transaction price of $9.26, positioning this recent purchase underwater in the market's immediate aftermath.

CEO/CFO buys 3,600 shares of GLSI at $9.88; 5 purchases in 3 weeks amid unprofitable operations and -41.1% YoY decline.

Snehal Patel, acting as CEO and CFO, purchased 3,600 shares at $9.88 on 2025-04-25, the fifth open-market buy in as many weeks (prior buys on 2025-04-17, 2025-04-07, 2025-04-04, 2025-01-10, and 2025-01-07). His same-ticker history at GLSI shows two measurable outcomes: the January 10 buy returned -25.5% over 90 days and the January 7 buy returned -30.2% over 90 days, with a timing pattern of 0 of 2 well-timed buys at the 90-day mark. The company is unprofitable (net income $-2,668,713.00 for the most recent full fiscal year) and the stock has declined -41.1% from its 52-week high of $17.58. The rapid succession of purchases at the CEO/CFO level warrants attention to whether the buying pattern reflects conviction or follows other factors, though the broader context of negative earnings and significant stock depreciation suggests material risk.